Express Scripts Announces Enhancements to Industry Leading SafeGuardRx(SM) Programs

Go back to Express Scripts Announces Enhancements to Industry Leading SafeGuardRx(SM) Programs

Mizuho Securities Remains Sidelined on Express Scripts (ESRX) Following 2017 Guidance

December 14, 2016 1:16 PM UTC

Mizuho Securities reiterated a Neutral rating and $76.00 price target on Express Scripts (NASDAQ: ESRX) following the company's initial 2017 guidance. 2017 adjusted EPS guidance is $6.82-$7.02, relatively in-line with consensus of $6.93 at the midpoint ($6.92), implies a +7-10% adjusted EPS growth y/y.

Analyst Ann Hynes commented,... More